Dr. Nunzio Pomara
Claim this profileKline Institute for Psychiatric Research
Studies Alzheimer's Disease
Studies Mild Cognitive Impairment
6 reported clinical trials
11 drugs studied
Area of expertise
1Alzheimer's Disease
APOE positive
APOE negative
APOE ε4 positive
2Mild Cognitive Impairment
Affiliated Hospitals
Clinical Trials Nunzio Pomara is currently running
Transcranial Photobiomodulation
for Alzheimer's Disease
This multi-site study will be the first to evaluate the dose-dependent effects of t-PBM in amnestic Mild Cognitive Impairment (aMCI) and early Alzheimer's Disease (AD) (CDR of 0.5-1, FAST 1-4; age 65-85) in a randomized clinical trial of 8 weeks of t-PBM vs. sham. At baseline, all subjects will complete initial neuropsychological testing. To elucidate mechanisms of action of t-PBM, prior to treatment, subjects will undergo neuroimaging related to critical features of AD: tau 18F MK-6240 load (PET), measures of brain bioenergetics (31P-MRS), and functional connectivity (rs-fMRI). After undergoing target engagement testing (t-PBM session performed during fMRI to detect BOLD changes with active t-PBM), subjects will then be randomized to t-PBM/sham and complete 24 t-PBM/sham treatments, \~11 min per day, 3 days per week, for 8 weeks. t-PBM will be administered via continuous, 808 nm wavelength laser delivery to the forehead bilaterally (at standard EEG electrode positions F4, F3).
Recruiting0 awards Phase 25 criteria
Escitalopram
for Depression and Alzheimer's Prevention
This trial will test if treating depression with the antidepressant escitalopram can affect biological markers related to Alzheimer's disease. It targets people with major depressive disorder to see if reducing their depression can also lower their risk of developing Alzheimer's. The study compares escitalopram to understand its effects on these markers. Escitalopram is commonly used to treat major depressive disorder.
Recruiting2 awards Phase 4
More about Nunzio Pomara
Clinical Trial Related3 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Nunzio Pomara has experience with
- ALZ-801
- Escitalopram Oxalate
- Placebo
- Transcranial Photobiomodulation
- None
- Amyvid
Breakdown of trials Nunzio Pomara has run
Alzheimer's Disease
Mild Cognitive Impairment
Major Depression
Major Depressive Disorder
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Nunzio Pomara specialize in?
Nunzio Pomara focuses on Alzheimer's Disease and Mild Cognitive Impairment. In particular, much of their work with Alzheimer's Disease has involved APOE positive patients, or patients who are APOE negative.
Is Nunzio Pomara currently recruiting for clinical trials?
Yes, Nunzio Pomara is currently recruiting for 2 clinical trials in Orangeburg New York. If you're interested in participating, you should apply.
Are there any treatments that Nunzio Pomara has studied deeply?
Yes, Nunzio Pomara has studied treatments such as ALZ-801, Escitalopram Oxalate, Placebo.
What is the best way to schedule an appointment with Nunzio Pomara?
Apply for one of the trials that Nunzio Pomara is conducting.
What is the office address of Nunzio Pomara?
The office of Nunzio Pomara is located at: Kline Institute for Psychiatric Research, Orangeburg, New York 10962 United States. This is the address for their practice at the Kline Institute for Psychiatric Research.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.